Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2018-02-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of
Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or
gastroesophageal junction adenocarcinoma.